The Role of Regucalcin in Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: 1 March 2025 | Viewed by 26
Special Issue Editor
Interests: cancer biology; bone metastasis; calcium and carcinogenesis; regucalcin and cancer suppressor; cell signaling
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer suppressor proteins play a key role in preventing the development of cancer. Many suppressor proteins have been identified thus far. TP53, Rb, and p21 are classically well-known as tumor suppressors. The elucidation of suppressor proteins may lead to the identification of a novel signaling pathway that regulates the cell proliferation and death of cancer cells. This may provide us with a new target for cancer control and therapy. In recent years, there has been increasing evidence that regucalcin, which was discovered to be a regulator in calcium signaling, plays a suppressive role in human cancer. The expression of the regucalcin gene, which is located in the X chromosome, may be downregulated during oncogenic processes, such as deletions, genetic rearrangements, epigenetic silencing of transcription, or post-translational modifications. Several tumor suppressors, such as TP53, are inactivated through mutations. Other tumor suppressors, such as CDKN2A, are often inactivated by deletions, mutations, or epigenetic silencing. To the best of our knowledge, there is no reported information regarding the mutations of the regucalcin gene that cause a downregulation of regucalcin expression in the context of cancer. Notably, regucalcin gene expression is known to be downregulated by dietary and drug intakes and various pathophysiological conditions, which is influenced by the attenuation of metabolic regulation and cell disorders. Regucalcin may be a unique factor in the context of cancer regulation. This Special Issue focuses on various aspects regarding the role of regucalcin in cancer regulation.
Prof. Dr. Masayoshi Yamaguchi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer suppressor protein
- cell signaling
- metabolic regulation
- transcription factor
- cell proliferation
- cell death
- drug development
- cancer therapy
